Lexicon Pharmaceuticals
LXRX
98 hedge funds and large institutions have $357M invested in Lexicon Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 38 increasing their positions, 22 reducing their positions, and 8 closing their positions.
230% more call options, than puts
Call options by funds: $287K | Put options by funds: $87K
163% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 8
73% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 22
62% more capital invested
Capital invested by funds: $221M → $357M (+$136M)
14% more funds holding
Funds holding: 86 → 98 (+12)
1.65% more ownership
Funds ownership: 79.42% → 81.07% (+1.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
+$51.5M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$10M |
| 3 |
JP Morgan Chase
New York
|
+$5.79M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$5.54M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.11M |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$832K |
| 3 |
IHAM
Integral Health Asset Management
New York
|
-$558K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$558K |
| 5 |
D.E. Shaw & Co
New York
|
-$510K |
LXRX Hedge Fund Activity: Q3 2022 in Review
98 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q3 2022, worth a combined $357M — up 62% from $221M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new LXRX positions and 8 closed out — a net gain of 13 holders — while 38 added to existing stakes and 22 trimmed.
The largest buyer was Artal Group, adding an estimated $51.5M. The largest seller was Morgan Stanley, cutting an estimated $1.11M.
- 98 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q3 2022, up from 86 in Q2 2022.
- Funds reported $357M of Lexicon Pharmaceuticals stock for Q3 2022, up 62% quarter-over-quarter.
- 21 funds opened new Lexicon Pharmaceuticals positions in Q3 2022 and 8 closed out, a net change of +13 holders.
- The largest Lexicon Pharmaceuticals buyer in Q3 2022 was Artal Group, an estimated $51.5M added.
- The largest Lexicon Pharmaceuticals seller in Q3 2022 was Morgan Stanley, an estimated $1.11M sold.
Based on aggregated 13F filings for Q3 2022.